These findings, the unexpected use of the distal and Liver promoters supplementing the Prox and Alt promoters of PPARGC1A in SkM, and the preferential use of the distal promoter in ESC need follow-up investigation given the importance of PPARGC1A transcription levels and isoform usage to exercise, aging, SkM hypertrophy, and disease, including facioscapulohumeral muscular dystrophy, Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and ischemia [50,51,63,83,84,85,86]. This evidence concerns the gene PPARGC1A and facioscapulohumeral muscular dystrophy.